A Digital Test for Toxic Genes
News Jan 30, 2014
Like little factories, cells metabolize raw materials and convert them into chemical compounds. Biotechnologists take advantage of this ability, using microorganisms to produce pharmaceuticals and biofuels. To boost output to an industrial scale and create new types of chemicals, biotechnologists manipulate the microorganisms' natural metabolism, often by "overexpressing" certain genes in the cell. But such metabolic engineering is hampered by the fact that many genes become toxic to the cell when overexpressed.
Now, Allon Wagner, Uri Gophna, and Eytan Ruppin of Tel Aviv University'sBlavatnik School of Computer Science and Department of Molecular Microbiology and Biotechnology, along with researchers at the Weizmann Institute of Science, have developed a computer algorithm that predicts which metabolic genes are lethal to cells when overexpressed. The findings, published in Proceedings of the National Academy of Sciences, could help guide metabolic engineering to produce new chemicals in more cost-effective ways.
"In the lab, biotechnologists often determine which genes can be overexpressed using trial and error," said Wagner. "We can save them a lot of time and money by ruling out certain possibilities and highlighting other, more promising ones."
Gaining an EDGE
When metabolic genes are expressed, the genetic information they contain is converted into proteins, which catalyze the chemical reactions necessary for life. Overexpression means that greater-than-normal amounts of proteins are produced. Biotechnologists typically overexpress native genes of an industrial microorganism to boost a certain metabolic pathway in the cell, thus increasing the production of desired compounds. Sometimes they overexpress foreign genes — genes transferred from other organisms — in an industrial microbe to build new metabolic pathways and allow it to synthesize new compounds. But they often find that their efforts are hindered by the toxicity of the genes that they wish to overexpress.
Prof. Ruppin's laboratory builds large-scale software models of cellular metabolism, one of the most fundamental aspects of life. These models convert physical, chemical, and biological information into a set of mathematical equations, allowing scientists to learn how cells work and explore what happens if they are tweaked in certain ways. The newly developed algorithm, Expression Dependent Gene Effects, or EDGE, predicts what happens if scientists manipulate cells to overexpress certain genes. EDGE allows biotechnologists to foresee cases in which the overexpressed genes become toxic and then direct their efforts toward other genes.
To validate their method, TAU researchers used genetic manipulation tools to overexpress 26 different genes in E. coli bacterial cells. Comparing the results of their computer simulations with the actual growth of the overexpressed strains that was measured in the lab, they saw that EDGE was able to predict which of the overexpressed genes turned out to be lethal to E. coli. EDGE was also successful in identifying cases of foreign genes that were toxic to E. coli, as the researchers learned from comparing the simulations' results with data collected by their collaborators at the Weizmann Institute of Science.
EDGE's applications appear to extend beyond bacteria. The researchers conducted tests showing that the genes EDGE predicted to be toxic when overexpressed are expressed at low levels not only in microorganisms like bacteria, but also in multicellular organisms, including humans. The researchers say these results reflect the vital evolutionary need to keep the expression of potentially deleterious genes in check.
"Although EDGE's current focus is biotechnology, gene overexpression also plays a central part in many human diseases, particularly in cancer. We hope that future work will apply EDGE to those directions," Wagner said.
Using Epigenetic Signatures and Machine Learning to Improve DiagnosisNews
Unique epigenetic signatures for nine neurodevelopmental disorders have been identified, lending to a better method of diagnosis for disorders with much clinical overlap.READ MORE
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE
Drug-like Compounds Reverse Chemotherapy Failure for 3 Aggressive CancersNews
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers -- ovarian, prostate and breast.READ MORE